Skip to search formSkip to main contentSkip to account menu

Multikinase Inhibitor 4SC-203

Known as: 4SC-203 
A multikinase inhibitor with potential antineoplastic activity. Multikinase inhibitor 4SC-203 selectively inhibits FMS-related tyrosine kinase 3… 
National Institutes of Health

Related topics

Related topics

1 relation
Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Involution of EruptiveMelanocytic Nevi on Combination BRAF andMEK Inhibitor Therapy
E ruptive melanocytic nevi (EMN) have been described as the sudden-onset development of numerous melanocytic nevi in association… 
2011
2011
Phase I dose-escalation study of sorafenib in combination with bevacizumab (B), paclitaxel (P), and carboplatin (C) for the treatment of advanced nonsquamous non-small cell lung cancer (NSCLC).
7565 Background: Sorafenib (S) is an oral multikinase inhibtor. The safety, antitumor activity, and pharmacokinetics of the… 
2011
2011
1251 POSTER Preclinical and Clinical Development of 4SC-203 – a Novel Multi-target Kinase Inhibitor
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)